在全膝关节整形术后,对血红蛋白水平的VTE预防剂的比较:基于医院信息系统的观察性研究
Liang Yuan1, Bin Sun1, Xing Xin1
1Department of Orthopaedics, Peking University International Hospital, Life Park Road No.1, Life Science Park of Zhongguancun, Changping District, Beijing, 102206, China.
Journal of orthopaedic surgery and research
|June 16, 2025
概括
手术后的血红蛋白水平在全膝关节整形术 (TKA) 后下降. 阿司匹林,里瓦罗克萨班和低分子量肝素 (LMWH) 在早期的Hb变化中没有显示出临床上显著的差异.
科学领域:
- 整形外科手术 整形外科手术
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
背景情况:
- 静脉血栓塞栓症 (VTE) 预防在像全膝关节整形术 (TKA) 这样的重大骨科手术后是必不可少的.
- 常见的静脉瘤预防剂对术后血红蛋白 (Hb) 水平的比较作用尚未得到充分证实.
研究的目的:
- 为了比较阿司匹林,里瓦罗克萨班和低分子量肝素 (LMWH) 对TKA后早期术后血红蛋白 (Hb) 变化的影响.
主要方法:
- 一个单一中心的回顾性队列研究包括655个初级TKA.
- 患者接受了用阿司匹林,里瓦罗克萨班或LMWH进行静脉瘤预防.
- 主要结局是从术后第一天降低Hb到出院前的最低水平.
主要成果:
- 在TKA后的第一周内观察到平均Hb下降13.9g/L.
- 与阿司匹林相比,里瓦罗克萨班和LMWH与更大的Hb降低有关.
- 尽管有统计差异,但效果大小小,表明缺乏临床意义.
结论:
- 在TKA后的第一周内,血红蛋白水平显著下降.
- 在阿司匹林,里瓦洛克萨班和LMWH之间没有发现早期术后Hb变化的临床意义上的差异.
相关概念视频
Venous Thrombosis III: Interprofessional Care
28
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
28
Anticoagulant Drugs: Low-Molecular-Weight Heparins
932
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
932
Venous Thrombosis IV: Nursing Management
27
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
27
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
43
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
43
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
260
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
260


